Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Molecular Templates collaborates with MD Anderson Cancer Center on MT-3724

Oct. 13, 2015

Altor receives NCI grant to support development of ALT-803 for NHL

Oct. 9, 2015

Nektar submits IND for NKTR-214 to treat solid tumor malignancies

Oct. 8, 2015

Avelumab receives FDA fast track designation for metastatic Merkel cell carcinoma

Oct. 8, 2015

GreenPeptide files IND for cancer peptide vaccine GRN-1201

Oct. 8, 2015

MedImmune initiates phase I study of MEDI-9197 for solid tumor cancers

Oct. 8, 2015

FDA places clinical hold on axalimogene filolisbac

Oct. 7, 2015

Biosimilar ONS-1045 meets primary and secondary endpoints in phase I trial

Oct. 7, 2015

Nivolumab shows enhanced overall survival in mRCC patients

Oct. 6, 2015

FDA approves Keytruda and companion diagnostic for PD-L1-expressing NSCLC tumors

Oct. 5, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...